leisure time -WSS

leisure time

author：Wikipedia 2025-08-23 08:57:19 - browse：32

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： FDA does about

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

RaDonda Vaught to speak at CommonSpirit event on patient safety

Pfizer highlights cancer drugs it thinks could reignite investor interest

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Patients' immediate access to test results puts radiologists in a bind

The woman behind the Dana Farber

leisure time

leisure time

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Congenital heart disease patients face new threat of heart failure

Duchenne breakthrough therapy leaves behind pioneering families

Kenai launches with $82 million for Parkinson’s stem cell therapy

Sports medicine is finally prioritizing gender equality

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Affirmative action in medical school literally saved lives

STAT letters to the editor on burnt

Malaria cases in Florida and Texas: Here’s what you need to know

Spinal cord stimulation reduces pain in amputees, study finds

explore

Biotech companies concerned about China biosecurity crackdown

Flu vaccine offering decent levels of protection this winter, new data show

FDA does about

Congenital heart disease patients face new threat of heart failure

Roche to buy Carmot Therapeutics, developer of obesity drugs

Scientists unlock the key to scar

hotspot

explore

explore

entertainment